The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: John Purtell - Macquarie Research - Analyst
: Look, just a few from me, if I can. Raj, just operationally, again, just picking up on Life Sciences, I mean, back in May, you did flag the potential for
weakness in some of the more cyclical areas of Life Sciences, so capital projects and infrastructure in markets like the U.S. How has that played out?
Because it would appear that it had a relatively minimal overall impact, which implies that the impacts have been minor from those discretionary
areas or there's been other offsetting positives?
Question: John Purtell - Macquarie Research - Analyst
: And just in relation to Geochem, obviously, price and mix have been a positive for you for the last -- certainly, in the last 12, 18 months. I mean, to
what extent has that been an ongoing positive for you in this period and help support margins?
Question: John Purtell - Macquarie Research - Analyst
: And just a couple of quick questions for Luis. In terms of cash flow and working capital, how have you seen that in terms of your working capital
and DSOs through the first quarter? And how are you managing markets like Latin America?
Question: John Purtell - Macquarie Research - Analyst
: And just the last one, Luis, in terms of restructuring costs, I mean, we've seen some of those sort of in the last few periods. Presumably, we may see
more below-the-line restructuring costs this period, given what's been a bigger head count reduction given global events?
|
